A Single and Multiple Dose Study of MK-6916 in Healthy Japanese Participants

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-6916 in Healthy Japanese Participants

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250190

Enrollment

Registered

2026-01-19

Start date

2026-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Panel A: MK-6916 50mg, 200mg, or 50mg (fed condition) administered as a single oral dose. Panel B: MK-6916 100mg or 400mg administered as a single oral dose. Panel C: MK-6916 300mg administered orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male participants and female participants of nonchildbearing potential between the ages of 18 and 60 years

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse events, discontinuation of study intervention due to adverse event(s).	—

Secondary

Measure	Time frame
Pharmacokineticks	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026